Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04984434 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma

Interventions

DRUG: F182112

Sponsor

Shandong New Time Pharmaceutical Co., LTD